Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 12/20 | 0.71 |
| ▸ | PIK3CA | P42336 | 8/20 | 0.71 |
| ▸ | PIK3CD | O00329 | 8/20 | 0.69 |
| ▸ | PIK3CG | P48736 | 8/20 | 0.69 |
| ▸ | PIK3CB | P42338 | 7/20 | 0.69 |
| ▸ | MTOR | P42345 | 7/20 | 0.60 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.59 |
| ▸ | PRKDC | P78527 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1650979 | 0.88 | AKT1 (0.73) | AKT1PIK3CAPIK3CDPIK3CGPIK3CB | |
| SCHEMBL1649960 | 0.87 | PIK3CA (0.66) | AKT1PIK3CAPIK3CDPIK3CGPIK3CB | |
| SCHEMBL7998274 | 0.83 | AKT1 (0.49) | AKT1PIK3CAPIK3CDPIK3CGPIK3CB | |
| SCHEMBL1651033 | 0.83 | PIK3CA (0.53) | AKT1PIK3CAPIK3CDPIK3CGPIK3CB | |
| SCHEMBL1619927 | 0.83 | AKT1 (1.00) | AKT1PIK3CAPIK3CDPIK3CGPIK3CB | |
| SCHEMBL7991464 | 0.82 | AKT1 (0.48) | AKT1PIK3CAPIK3CDPIK3CGPIK3CB | |
| SCHEMBL924973 | 0.81 | PIK3CB (1.00) | AKT1PIK3CAPIK3CDPIK3CGPIK3CB | |
| SCHEMBL4509793 | 0.79 | PIK3CD (0.77) | AKT1PIK3CAPIK3CDPIK3CGPIK3CB | |
| SCHEMBL4524145 | 0.78 | PIK3CD (0.76) | AKT1PIK3CAPIK3CDPIK3CGPIK3CB | |
| SCHEMBL1556847 | 0.78 | PIK3CA (0.47) | AKT1PIK3CAPIK3CGPIK3CBMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178070-A1 | PI3K/mTOR INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-07-21 | — | — | US | claimed |
| EP-2311842-A2 | PI3K/M TOR inhibitors | Takeda Pharmaceutical Company Limited (JP) | 2011-04-20 | — | — | EP | claimed |
| US-20110178070-A1 | PI3K/mTOR INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-07-21 | — | — | US | disclosed |
| US-20110178070-A1 | PI3K/mTOR INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-07-21 | — | — | US | disclosed |
| US-20110178070-A1 | PI3K/mTOR INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-07-21 | — | — | US | disclosed |
| EP-2311842-A2 | PI3K/M TOR inhibitors | Takeda Pharmaceutical Company Limited (JP) | 2011-04-20 | — | — | EP | disclosed |
| EP-2303886-A2 | PI3K/M TOR INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2011-04-06 | — | — | EP | disclosed |
| WO-2010008847-A2 | PI3K/M TOR INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-21 | — | — | WO | disclosed |
| WO-2010008847-A2 | PI3K/M TOR INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178070-A1 | PI3K/mTOR INHIBITORS | MTOR, RICTOR, PIK3CA | AKT1 20/4885PIK3CA 3/4885PIK3CD 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.